The majority of embolic strokes in patients with nonvalvular atrial fibrillation are caused by
thrombi in the left atrial appendage. It is projected that strokes related to atrial fibrillation will …

Objectives This study aimed to provide a systematic review of device‐associated thrombosis
(DAT) after left atrial appendage occlusion (LAAO) with the Watchman, Amplatzer Cardiac …

Exclusion of the left atrial appendage to reduce thromboembolic risk related to atrial
fibrillation was first performed surgically in 1949. Over the past 2 decades, the field of …

Background: Left atrial appendage closure (LAAC) was approved by the US Food and Drug
Administration (FDA) as a stroke prevention alternative to warfarin for patients with …

In 2019, the Guidelines for non-pharmacotherapy of cardiac arrhythmias (JCS/JHRS 2019)
were published, covering areas such as treatment using cardiac electrical implantable …

Device embolization is a rare complication of transcatheter structural heart interventions.
Although the majority of device embolizations can be treated in a semielective manner …

Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and
mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly …

Left atrial appendage (LAA) closure has evolved as an effective strategy for stroke
prevention in patients with atrial fibrillation who are considered suitable for oral …

Major procedural complications related to left atrial appendage occlusion (LAAO) are
relatively infrequent but may be associated with major morbidity and mortality. LAAO …

Prevention of stroke represents a goal of primary importance in health systems due to its
associated morbidity and mortality. As several patient groups with increased stroke rates …